通益风宁治疗痛风的临床观察

A clinical trial of allo. comp. ratiopharm on treating gout

本文通过前瞻性双盲对比临床研究以评价通益风宁降低血尿酸的效能和耐受性。３４例痛风或高尿酸血症患者随机每天口服一片通益风宁（含别嘌呤醇１００ｍｇ和苯溴马龙２０ｍｇ）或别嘌呤醇１００ｍｇ，共２周。结果通益风宁组（ｎ＝２２）血尿酸下降的幅度显著大于别嘌呤醇组（ｎ＝１２，Ｐ＜０．０１），而尿尿酸排泄的下降幅度则显著低于别嘌呤醇组（Ｐ＜０．０１），提示通益风宁的降血尿酸作用比别嘌呤醇强。本组观察未发现通益风宁有严重的副作用。

The aim of this study was to evaluate the efficacy and tolerance of allo. comp. ratiopharm on lowering serum uric acid in patients with gout or hyperuricemia by a prospective, double blind, comparative clinical trial. Thirty four patients with gout or hyperuricemia randomly took one tablet of allo. comp. (containing 100mg allopurinol and 20mg benzbromarone) or 100mg allopurinol daily for 2 weeks. It was found that the mean decrease of serum uric acid in allo. comp. group ( n =22) was significently greater than that in allopurinol group ( n =12, P <0.01), whereas, the mean reduction of urinary uric acid excretion in allo. comp. group was significantly less than that in allopurinol group. The results suggested that allo. comp had stronger efficacy on lowering serum uric acid. Serere side effects were not found in patients taking allo. comp.